Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2a Study of Gemcitabine and Nab-paclitaxel in Combination With Avutometinib (VS-6766) and Defactinib in Patients With Previously Untreated Metastatic Adenocarcinoma of the Pancreas

Next Previous
Search
Trial Profile

A Phase 1b/2a Study of Gemcitabine and Nab-paclitaxel in Combination With Avutometinib (VS-6766) and Defactinib in Patients With Previously Untreated Metastatic Adenocarcinoma of the Pancreas

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avutometinib (Primary) ; Defactinib (Primary) ; Gemcitabine; Paclitaxel
  • Indications Adenocarcinoma; Pancreatic ductal carcinoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms RAMP 205
  • Sponsors Verastem Oncology

    • Most Recent Events

    • 23 Jan 2025 According to a Verastem Oncology media release, company to report updated data from the ongoing RAMP 205 trial in Q1 2025 and present data at a medical meeting in mid-year 2025 and company will choose a Recommended Phase 2 Dose (RP2D) for trial expansion in H1 2025.
    • 29 Jul 2024 According to a Verastem Oncology media release, company expects to report updated data from the ongoing RAMP 205 trial in first-line metastatic pancreatic cancer in Q1 2025.
    • 04 Jun 2024 Results (At the 24Jan2024 data cutoff, n=81)presented at the 60th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top